TY - JOUR
T1 - Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention
T2 - current status and future possibilities
AU - Playdon, Mary C.
AU - Hardikar, Sheetal
AU - Karra, Prasoona
AU - Hoobler, Rachel
AU - Ibele, Anna R.
AU - Cook, Katherine L.
AU - Kumar, Amanika
AU - Ippolito, Joseph E.
AU - Brown, Justin C.
N1 - Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].
PY - 2023/5/4
Y1 - 2023/5/4
N2 - Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.
AB - Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.
UR - http://www.scopus.com/inward/record.url?scp=85159544630&partnerID=8YFLogxK
U2 - 10.1093/jncimonographs/lgad003
DO - 10.1093/jncimonographs/lgad003
M3 - Article
C2 - 37139980
AN - SCOPUS:85159544630
SN - 1052-6773
VL - 2023
SP - 68
EP - 76
JO - Journal of the National Cancer Institute. Monographs
JF - Journal of the National Cancer Institute. Monographs
IS - 61
ER -